Clinical and histopathological predictors of outcome in malignant meningioma

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Clinical and histopathological predictors of outcome in malignant meningioma. / Maier, Andrea D.; Bartek, Jiri; Eriksson, Frank; Ugleholdt, Heidi; Juhler, Marianne; Broholm, Helle; Mathiesen, Tiit I.

In: Neurosurgical Review, 2019.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Maier, AD, Bartek, J, Eriksson, F, Ugleholdt, H, Juhler, M, Broholm, H & Mathiesen, TI 2019, 'Clinical and histopathological predictors of outcome in malignant meningioma', Neurosurgical Review. https://doi.org/10.1007/s10143-019-01093-5

APA

Maier, A. D., Bartek, J., Eriksson, F., Ugleholdt, H., Juhler, M., Broholm, H., & Mathiesen, T. I. (2019). Clinical and histopathological predictors of outcome in malignant meningioma. Neurosurgical Review. https://doi.org/10.1007/s10143-019-01093-5

Vancouver

Maier AD, Bartek J, Eriksson F, Ugleholdt H, Juhler M, Broholm H et al. Clinical and histopathological predictors of outcome in malignant meningioma. Neurosurgical Review. 2019. https://doi.org/10.1007/s10143-019-01093-5

Author

Maier, Andrea D. ; Bartek, Jiri ; Eriksson, Frank ; Ugleholdt, Heidi ; Juhler, Marianne ; Broholm, Helle ; Mathiesen, Tiit I. / Clinical and histopathological predictors of outcome in malignant meningioma. In: Neurosurgical Review. 2019.

Bibtex

@article{8b4733d8ac3a4aa388b26a3303c4d10c,
title = "Clinical and histopathological predictors of outcome in malignant meningioma",
abstract = "We investigated possible clinical and histopathological prognostic factors in a malignant meningioma cohort with comprehensive long-term population-based follow-up data. Twenty-four consecutive patients treated surgically for malignant meningioma at the Department of Neurosurgery and the Department of Pathology, Rigshospitalet, Copenhagen, Denmark, from December 2000 to March 2014 were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS). Clinical parameters were recorded. All specimens underwent immunohistochemical analysis for Ki-67 and phosphohistone-H3 (PHH3). Prognostication was assessed with Cox proportional hazard regression analysis. The median follow-up was 46.1 months (range 0.7-150.7). The median progression-free survival was 16.5 months (95{\%} CI 11.4-43.0) and the median overall survival was 46.6 months (95{\%} CI 20.4-NA). Six patients were alive at the end of follow-up; two of these had not experienced a recurrence. No clinical parameter showed significant association with PFS or OS. Mitotic index (MI) was significantly associated with PFS and OS, and PHH3 MI with PFS. Immunohistochemical reactivity of Ki-67 > 10{\%} was a negative predictor of PFS (HR 3.92, 95{\%} CI 1.47-10.4, p = 0.0063) and OS (HR 3.35, 95{\%} CI 1.12-10.1, p = 0.0313). The histological subgrouping of grade III meningioma into anaplastic and non-anaplastic revealed increased PFS for the latter (HR 4.57, CI 95{\%} 1.32-15.7, p = 0.0164). We could not verify previous clinical parameters as prognostic factors in malignant meningioma. MI and the PHH3 MI were prognostic within WHO grade III meningiomas for PFS. An overall tumor staining of Ki-67 > 10{\%} correlated with PFS and OS within grade III tumors.",
author = "Maier, {Andrea D.} and Jiri Bartek and Frank Eriksson and Heidi Ugleholdt and Marianne Juhler and Helle Broholm and Mathiesen, {Tiit I}",
year = "2019",
doi = "10.1007/s10143-019-01093-5",
language = "English",
journal = "Neurosurgical Review",
issn = "0344-5607",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Clinical and histopathological predictors of outcome in malignant meningioma

AU - Maier, Andrea D.

AU - Bartek, Jiri

AU - Eriksson, Frank

AU - Ugleholdt, Heidi

AU - Juhler, Marianne

AU - Broholm, Helle

AU - Mathiesen, Tiit I

PY - 2019

Y1 - 2019

N2 - We investigated possible clinical and histopathological prognostic factors in a malignant meningioma cohort with comprehensive long-term population-based follow-up data. Twenty-four consecutive patients treated surgically for malignant meningioma at the Department of Neurosurgery and the Department of Pathology, Rigshospitalet, Copenhagen, Denmark, from December 2000 to March 2014 were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS). Clinical parameters were recorded. All specimens underwent immunohistochemical analysis for Ki-67 and phosphohistone-H3 (PHH3). Prognostication was assessed with Cox proportional hazard regression analysis. The median follow-up was 46.1 months (range 0.7-150.7). The median progression-free survival was 16.5 months (95% CI 11.4-43.0) and the median overall survival was 46.6 months (95% CI 20.4-NA). Six patients were alive at the end of follow-up; two of these had not experienced a recurrence. No clinical parameter showed significant association with PFS or OS. Mitotic index (MI) was significantly associated with PFS and OS, and PHH3 MI with PFS. Immunohistochemical reactivity of Ki-67 > 10% was a negative predictor of PFS (HR 3.92, 95% CI 1.47-10.4, p = 0.0063) and OS (HR 3.35, 95% CI 1.12-10.1, p = 0.0313). The histological subgrouping of grade III meningioma into anaplastic and non-anaplastic revealed increased PFS for the latter (HR 4.57, CI 95% 1.32-15.7, p = 0.0164). We could not verify previous clinical parameters as prognostic factors in malignant meningioma. MI and the PHH3 MI were prognostic within WHO grade III meningiomas for PFS. An overall tumor staining of Ki-67 > 10% correlated with PFS and OS within grade III tumors.

AB - We investigated possible clinical and histopathological prognostic factors in a malignant meningioma cohort with comprehensive long-term population-based follow-up data. Twenty-four consecutive patients treated surgically for malignant meningioma at the Department of Neurosurgery and the Department of Pathology, Rigshospitalet, Copenhagen, Denmark, from December 2000 to March 2014 were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS). Clinical parameters were recorded. All specimens underwent immunohistochemical analysis for Ki-67 and phosphohistone-H3 (PHH3). Prognostication was assessed with Cox proportional hazard regression analysis. The median follow-up was 46.1 months (range 0.7-150.7). The median progression-free survival was 16.5 months (95% CI 11.4-43.0) and the median overall survival was 46.6 months (95% CI 20.4-NA). Six patients were alive at the end of follow-up; two of these had not experienced a recurrence. No clinical parameter showed significant association with PFS or OS. Mitotic index (MI) was significantly associated with PFS and OS, and PHH3 MI with PFS. Immunohistochemical reactivity of Ki-67 > 10% was a negative predictor of PFS (HR 3.92, 95% CI 1.47-10.4, p = 0.0063) and OS (HR 3.35, 95% CI 1.12-10.1, p = 0.0313). The histological subgrouping of grade III meningioma into anaplastic and non-anaplastic revealed increased PFS for the latter (HR 4.57, CI 95% 1.32-15.7, p = 0.0164). We could not verify previous clinical parameters as prognostic factors in malignant meningioma. MI and the PHH3 MI were prognostic within WHO grade III meningiomas for PFS. An overall tumor staining of Ki-67 > 10% correlated with PFS and OS within grade III tumors.

U2 - 10.1007/s10143-019-01093-5

DO - 10.1007/s10143-019-01093-5

M3 - Journal article

JO - Neurosurgical Review

JF - Neurosurgical Review

SN - 0344-5607

ER -

ID: 215142135